Clinuvel Pharmaceuticals (CLVLY)

[FarmaZutical]

I think Wolgen is only focusing on on-label. In an interview some years back he said that the 'clever' ones realize that this is where the money is, and that all talk of off label is counter productive. I agree. EPP + Vitiligo holds tremendous value. Add some label extensions and perhaps an out license or two to BP on other non dermatological indications and $200 is not pie in the sky. I think Wolgen's strategy is to make Clinuvel as valuable as possible focusing on high EPP pricing and subsequently Vitiligo. The joker IMO is wether try will take on a partner in the US for Vitiligo.